CareDx, Inc. (CDNA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$85.86-2.95%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · CDNA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks CDNA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Third Quarter 2026 Financial Highlights • Revenue of $139 million, an increase of 39% year-over-year • Testing Services revenue of $119 million, an increase of 65% year-over-year • Testing Services v…
Stated in 3 of 3 supplied quarters. Management reported: “About CareDx CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy.” “Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes.” Revenue was $139.362 million in 2026-Q3.
“Third Quarter 2026 Financial Highlights • Revenue of $139 million, an increase of 39% year-over-year • Testing Services revenue of $119 million, an increase of 65% year-over-year • Testing Services v…”
“Second Quarter 2026 Financial Highlights • Revenue of $132 million, an increase of 52% year-over-year • Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Servic…”
“First Quarter 2026 Financial Highlights · Revenue of $118 million, an increase of 39% year-over-year · Testing services revenue of $91 million, an increase of 48% year-over-year, and testing services…”
For more information, please visit www.caredx.com.
Stated in 3 of 3 supplied quarters. Management reported: “For more information, please visit www.caredx.com.” “Forward-Looking Statements This press release includes forward-looking statements, including expectations regarding the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026 and beyond.”
“For more information, please visit www.caredx.com.”
Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements.
Stated in 2 of 3 supplied quarters. Management reported: “Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements.” “For more information, please visit www.caredx.com.”
“Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements.”
“This transaction sharpens CareDx’s focus on our core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, where our integrated model continues to deliver strong growth,” said…
Stated in 1 of 3 supplied quarters. Management reported: ““And we took important strategic steps advancing our lead pipeline asset, AlloHeme, and agreeing to divest the Lab Products business to simplify our operating model and create focus, with the goal of expanding our AEBITDA margins.”” ““This transaction sharpens CareDx’s focus on our core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, where our integrated model continues to deliver strong growth,” said John Hanna, President and Chief Executive Officer of CareDx.”
Advance AlloHeme and HistoMap programs toward availability while building clinical evidence for the company's molecular testing portfolio.
Over the trailing year it converted 0.32x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.
“Adjusted EBITDA was $25 million, compared to $5 million in the second quarter of 2025, driven by strong Testing Services revenue growth, improved gross profit, and continued focus on operational effi…”
“Adjusted EBITDA was $19 million, compared to $5 million in the first quarter of 2025, driven by revenue growth and continued focus on operational efficiency and cost discipline.”
“For more information, please visit www.caredx.com.”
““And we took important strategic steps advancing our lead pipeline asset, AlloHeme, and agreeing to divest the Lab Products business to simplify our operating model and create focus, with the goal of…”